New drug enters final testing for Tough-to-Treat blood cancer
NCT ID NCT06122389
Summary
This study aims to see if a new drug called SHR2554 works better than an existing drug, chidamide, for adults with a type of blood cancer called PTCL that has come back or hasn't responded to prior treatment. It's a large, late-stage trial where neither the doctors nor the patients know which drug is being given. The main goal is to see which drug keeps the cancer from getting worse for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PTCLT WITH AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.